BlueWind Medical Secures $47.8 Million Financing to Accelerate Commercialization of Revi® System

Funds will fuel sales team expansion and broader market access, advancing the company's leadership in Implantable Tibial Neuromodulation (ITNM) for the treatment of urgency urinary incontinence (UUI)

SALT LAKE CITY--(BUSINESS WIRE)--BlueWind Medical, Ltd., a leader in Implantable Tibial Neuromodulation (ITNM) and developer of the Revi® System, a patient-centric solution for urgency urinary incontinence (UUI), today announced the close of $47.8 million in financing through a combination of equity and debt.

Proceeds from the financing will be used to further commercialization efforts for the Revi® System, including the continued expansion of the company's commercial sales organization and ongoing investment in market access initiatives that broaden patient and provider access to the therapy.

"Urgency urinary incontinence affects millions of people, creating a significant need for effective, durable treatment options that fit seamlessly into patients’ lives," said Kerry Nelson, Chief Executive Officer of BlueWind Medical. "This financing reflects deep conviction in our team, our technology, and the opportunity ahead to establish Revi as the new standard of care."

The financing builds on a series of clinical achievements over the past year, including three-year results from the pivotal OASIS study that confirmed Revi's sustained efficacy, excellent safety, and 95% patient satisfaction at 36 months.¹

"This financing is an important milestone for BlueWind and a strong validation of the progress we are making as a leader in Implantable Tibial Neuromodulation for urgency urinary incontinence," said Stephen Armstrong, Chief Financial Officer of BlueWind Medical. "The capital allows us to scale our commercial organization, expand market access, and ensure that more patients and providers can benefit from a clinically proven, patient-centric therapy. We are grateful for the continued confidence of our investors as we execute on the next phase of our growth."

About the Revi® System

Revi® is an innovative Implantable Tibial Neuromodulation (ITNM) device designed for the treatment of urgency urinary incontinence (UUI). Implanted near the ankle in a single outpatient procedure under local anesthesia, Revi delivers targeted stimulation to the posterior tibial nerve via a lightweight, external wearable. This design offers patients a simple, durable, and effective long-term solution for UUI symptom relief. Patients activate therapy once daily at home, without the need for internal batteries or leads, avoiding complications such as lead fracture, migration, or battery depletion.

About BlueWind Medical Ltd.

BlueWind Medical is transforming the field of neuromodulation therapy through the development of innovative, patient-centric medical technology for the treatment of disease. BlueWind is committed to enhancing the quality of life and overall well-being of patients with an initial focus on those living with urgency urinary incontinence (UUI). BlueWind’s Revi® System is the first and only Implantable Tibial Neuromodulation (ITNM) device activated by a battery-operated external wearable to receive FDA clearance for the treatment of patients with UUI. For additional information about BlueWind Medical, please visit bluewindmedical.com.

^1Amundsen CL, Sutherland SE, Heesakkers JPFA, Toozs-Hobson P, Martens F, McCrery RJ, et al. Three-Year Efficacy and Safety of Revi Implantable Tibial Neuromodulation from the Pivotal OASIS Study. Journal of Urology. 2026 April; 0(0): https://doi.org/10.1097/JU.0000000000005062